Literature DB >> 2297047

A 22-kd surface antigen detected by monoclonal antibody E 48 is exclusively expressed in stratified squamous and transitional epithelia.

J J Quak1, A J Balm, G A van Dongen, J G Brakkee, R J Scheper, G B Snow, C J Meijer.   

Abstract

After immunization of mice with viable cells of a metastasis of a laryngeal squamous cell carcinoma, a monoclonal antibody E 48 was obtained that detects an epitope present exclusively in squamous and transitional epithelium and their neoplastic counterparts. Immunoblotting revealed that E 48 recognizes a 22 kd molecule. Seventy-five of 76 squamous cell carcinomas from the head and neck, lung, cervix, and skin stained positively, whereas various adenocarcinomas from the colon, lung, and breast, and small cell lung carcinomas consistently stained negatively. The E 48 antigen, which is formaldehyde resistant, appears to be a reliable marker for differentiation of squamous cell carcinomas from adenocarcinoma, and small cell carcinomas.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297047      PMCID: PMC1877446     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  12 in total

1.  Detection of monoclonal antibodies specific for carbohydrate epitopes using periodate oxidation.

Authors:  M P Woodward; W W Young; R A Bloodgood
Journal:  J Immunol Methods       Date:  1985-04-08       Impact factor: 2.303

2.  Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors.

Authors:  L C Peters; J S Brandhorst; M G Hanna
Journal:  Cancer Res       Date:  1979-04       Impact factor: 12.701

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 4.  Pulmonary cytology: current status of cytologic typing of respiratory tract tumors.

Authors:  F G Hess; E M McDowell; B F Trump
Journal:  Am J Pathol       Date:  1981-05       Impact factor: 4.307

5.  Intrasplenic primary immunization for the production of monoclonal antibodies.

Authors:  M Spitz; L Spitz; R Thorpe; E Eugui
Journal:  J Immunol Methods       Date:  1984-05-11       Impact factor: 2.303

6.  Histopathologic classification of small cell lung cancer. Changing concepts and terminology.

Authors:  F R Hirsch; M J Matthews; S Aisner; O Campobasso; J D Elema; A F Gazdar; B Mackay; M Nasiell; Y Shimosato; R H Steele
Journal:  Cancer       Date:  1988-09-01       Impact factor: 6.860

7.  Iodination of monoclonal antibodies for diagnosis and radiotherapy using a convenient one vial method.

Authors:  H J Haisma; J Hilgers; V R Zurawski
Journal:  J Nucl Med       Date:  1986-12       Impact factor: 10.057

8.  Involucrin in lung tumors. A specific marker for squamous differentiation.

Authors:  J W Said; G Nash; A F Sassoon; I P Shintaku; S Banks-Schlegel
Journal:  Lab Invest       Date:  1983-11       Impact factor: 5.662

9.  Large cell neuroendocrine tumors of the lung. Clinical significance and histopathologic definition.

Authors:  M E Hammond; W T Sause
Journal:  Cancer       Date:  1985-10-01       Impact factor: 6.860

10.  Tissue distribution of keratin 7 as monitored by a monoclonal antibody.

Authors:  F Ramaekers; A Huysmans; G Schaart; O Moesker; P Vooijs
Journal:  Exp Cell Res       Date:  1987-05       Impact factor: 3.905

View more
  17 in total

1.  Peroxisome proliferator-activated receptor alpha-dependent induction of cell surface antigen Ly-6D gene in the mouse liver.

Authors:  S S Dadras; W S Cook; A V Yeldandi; W Q Cao; M S Rao; Z Wang; J K Reddy
Journal:  Gene Expr       Date:  2001

Review 2.  Current perspectives in the use of monoclonal antibodies for detection and treatment of head and neck tumors.

Authors:  J Quak; G van Dongen
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

3.  Micrometastases from squamous cell carcinoma in neck dissection specimens.

Authors:  M W van den Brekel; H V Stel; P van der Valk; I van der Waal; C J Meyer; G B Snow
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

4.  Up-regulation of lymphocyte antigen 6 complex expression in side-population cells derived from a human trophoblast cell line HTR-8/SVneo.

Authors:  Tetsunori Inagaki; Soshi Kusunoki; Kouichi Tabu; Hitomi Okabe; Izumi Yamada; Tetsuya Taga; Akemi Matsumoto; Shintaro Makino; Satoru Takeda; Kiyoko Kato
Journal:  Hum Cell       Date:  2015-07-30       Impact factor: 4.174

5.  Use of monoclonal antibody E48 in diagnosing transitional cell carcinoma of urinary bladder.

Authors:  R Torenbeek; C E Blomjous; J J Quak; S Ybema; C J Meijer
Journal:  J Clin Pathol       Date:  1992-04       Impact factor: 3.411

6.  Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer.

Authors:  R H Brakenhoff; F B van Gog; J E Looney; M van Walsum; G B Snow; G A van Dongen
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968

7.  Complete ablation of small squamous cell carcinoma xenografts with 186Re-labeled monoclonal antibody E48.

Authors:  M Gerretsen; G W Visser; R H Brakenhoff; M van Walsum; G B Snow; G A van Dongen
Journal:  Cell Biophys       Date:  1994

8.  Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas.

Authors:  R Moll; X R Wu; J H Lin; T T Sun
Journal:  Am J Pathol       Date:  1995-11       Impact factor: 4.307

9.  The utility of molecular diagnostics to predict recurrence of head and neck carcinoma.

Authors:  C Pena Murillo; X Huang; A Hills; M McGurk; A Lyons; J-P Jeannon; E Odell; A Brown; K Lavery; W Barrett; M Sherriff; R Brakenhoff; M Partridge
Journal:  Br J Cancer       Date:  2012-08-23       Impact factor: 7.640

10.  Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.

Authors:  M Gerretsen; A H Schrijvers; M van Walsum; B J Braakhuis; J J Quak; C J Meijer; G B Snow; G A van Dongen
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.